Questcor Pharmaceuticals Inc. (QCOR): Today's Featured Drugs Loser

Questcor Pharmaceuticals ( QCOR) pushed the Drugs industry lower today making it today's featured Drugs loser. The industry as a whole closed the day up 1.4%. By the end of trading, Questcor Pharmaceuticals fell $1.18 (-2.8%) to $40.48 on heavy volume. Throughout the day, 4.7 million shares of Questcor Pharmaceuticals exchanged hands as compared to its average daily volume of 1.9 million shares. The stock ranged in price between $38-$42.80 after having opened the day at $42.19 as compared to the previous trading day's close of $41.66. Other company's within the Drugs industry that declined today were: Idera Pharmaceuticals ( IDRA), down 20.3%, NeurogesX ( NGSX), down 10.8%, Chemocentryx ( CCXI), down 8.5%, and Anthera Pharmaceuticals ( ANTH), down 7.5%.

Questcor Pharmaceuticals, Inc., a biopharmaceutical company, provides prescription drugs for the treatment of multiple sclerosis, nephrotic syndrome, and infantile spasms indications. It primarily offers H.P. Questcor Pharmaceuticals has a market cap of $2.64 billion and is part of the health care sector. The company has a P/E ratio of 34.5, equal to the average drugs industry P/E ratio and above the S&P 500 P/E ratio of 17.7. Shares are up 0.5% year to date as of the close of trading on Tuesday. Currently there are eight analysts that rate Questcor Pharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates Questcor Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, expanding profit margins and good cash flow from operations. We feel these strengths outweigh the fact that the company is trading at a premium valuation based on our review of its current price compared to such things as earnings and book value.

On the positive front, Medgenics ( MDGN), up 23.5%, Amyris ( AMRS), up 19.2%, Accelr8 Technology Corporation ( AXK), up 18.1%, and Biodel ( BIOD), up 15.2%, were all gainers within the drugs industry with Johnson & Johnson ( JNJ) being today's featured drugs industry winner.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).